These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
180 related articles for article (PubMed ID: 26548355)
1. Effects of the Cessation of Mass Screening for Neuroblastoma at 6 Months of Age: A Population-Based Study in Osaka, Japan. Ioka A; Inoue M; Yoneda A; Nakamura T; Hara J; Hashii Y; Sakata N; Yamato K; Tsukuma H; Kawa K J Epidemiol; 2016; 26(4):179-84. PubMed ID: 26548355 [TBL] [Abstract][Full Text] [Related]
2. The incidence and mortality rates of neuroblastoma cases before and after the cessation of the mass screening program in Japan: A descriptive study. Shinagawa T; Kitamura T; Katanoda K; Matsuda T; Ito Y; Sobue T Int J Cancer; 2017 Feb; 140(3):618-625. PubMed ID: 27778323 [TBL] [Abstract][Full Text] [Related]
3. Neuroblastoma trends in Osaka, Japan, and Great Britain 1970-1994, in relation to screening. Honjo S; Doran HE; Stiller CA; Ajiki W; Tsukuma H; Oshima A; Coleman MP Int J Cancer; 2003 Feb; 103(4):538-43. PubMed ID: 12478672 [TBL] [Abstract][Full Text] [Related]
4. Effects of mass screening for neuroblastoma on incidence, mortality, and survival rates in Osaka, Japan. Ajiki W; Tsukuma H; Oshima A; Kawa K Cancer Causes Control; 1998 Dec; 9(6):631-6. PubMed ID: 10189049 [TBL] [Abstract][Full Text] [Related]
5. Effectiveness of screening for neuroblastoma at 6 months of age: a retrospective population-based cohort study. Hiyama E; Iehara T; Sugimoto T; Fukuzawa M; Hayashi Y; Sasaki F; Sugiyama M; Kondo S; Yoneda A; Yamaoka H; Tajiri T; Akazawa K; Ohtaki M Lancet; 2008 Apr; 371(9619):1173-80. PubMed ID: 18395578 [TBL] [Abstract][Full Text] [Related]
6. Italian cancer figures, report 2012: Cancer in children and adolescents. ; ; Epidemiol Prev; 2013; 37(1 Suppl 1):1-225. PubMed ID: 23585445 [TBL] [Abstract][Full Text] [Related]
7. Effects of mass screening on age-specific incidence of neuroblastoma. Bessho F Int J Cancer; 1996 Aug; 67(4):520-2. PubMed ID: 8759611 [TBL] [Abstract][Full Text] [Related]
8. A population-based study of the usefulness of screening for neuroblastoma. Woods WG; Tuchman M; Robison LL; Bernstein M; Leclerc JM; Brisson LC; Brossard J; Hill G; Shuster J; Luepker R; Byrne T; Weitzman S; Bunin G; Lemieux B Lancet; 1996 Dec 21-28; 348(9043):1682-7. PubMed ID: 8973429 [TBL] [Abstract][Full Text] [Related]
9. Secular trends in neuroblastoma mortality before and after the cessation of national mass screening in Japan. Katanoda K; Hayashi K; Yamamoto K; Sobue T J Epidemiol; 2009; 19(5):266-70. PubMed ID: 19652443 [TBL] [Abstract][Full Text] [Related]
10. Risks and benefits of ending of mass screening for neuroblastoma at 6 months of age in Japan. Tajiri T; Souzaki R; Kinoshita Y; Tanaka S; Koga Y; Suminoe A; Matsuzaki A; Hara T; Taguchi T J Pediatr Surg; 2009 Dec; 44(12):2253-7. PubMed ID: 20006005 [TBL] [Abstract][Full Text] [Related]
11. Mass screening and age-specific incidence of neuroblastoma in Saitama Prefecture, Japan. Yamamoto K; Hayashi Y; Hanada R; Kikuchi A; Ichikawa M; Tanimura M; Yoshioka S J Clin Oncol; 1995 Aug; 13(8):2033-8. PubMed ID: 7636545 [TBL] [Abstract][Full Text] [Related]
12. Neuroblastoma mass screening in late infancy: insights into the biology of neuroblastic tumors. Kerbl R; Urban CE; Ambros IM; Dornbusch HJ; Schwinger W; Lackner H; Ladenstein R; Strenger V; Gadner H; Ambros PF J Clin Oncol; 2003 Nov; 21(22):4228-34. PubMed ID: 14615452 [TBL] [Abstract][Full Text] [Related]
13. Marginal decrease in mortality and marked increase in incidence as a result of neuroblastoma screening at 6 months of age: cohort study in seven prefectures in Japan. Yamamoto K; Ohta S; Ito E; Hayashi Y; Asami T; Mabuchi O; Higashigawa M; Tanimura M J Clin Oncol; 2002 Mar; 20(5):1209-14. PubMed ID: 11870162 [TBL] [Abstract][Full Text] [Related]
14. Effectiveness of nationwide screening program for neuroblastoma in Japan. Hisashige A; Glob J Health Sci; 2014 Apr; 6(4):94-106. PubMed ID: 25001552 [TBL] [Abstract][Full Text] [Related]
15. Neuroblastoma: epidemiology and pattern of regression. Problems in interpreting results of mass screening. Carlsen NL Am J Pediatr Hematol Oncol; 1992 May; 14(2):103-10. PubMed ID: 1530115 [TBL] [Abstract][Full Text] [Related]
16. Mass screening for neuroblastoma: quo vadis? A 9-year experience from the Pediatric Oncology Study Group of the Kyushu area in Japan. Suita S; Zaizen Y; Sera Y; Takamatsu H; Mizote H; Ohgami H; Kurosaki N; Ueda K; Tasaka H; Miyazaki S; Sugimoto T; Kawakami K; Tsuneyoshi M; Yano H; Akiyama H; Ikeda K J Pediatr Surg; 1996 Apr; 31(4):555-8. PubMed ID: 8801312 [TBL] [Abstract][Full Text] [Related]
17. Neuroblastoma: changing incidence and survival in young people aged 0-24 years. A report from the North of England Young Persons' Malignant Disease Registry. Cotterill SJ; Parker L; More L; Craft AW Med Pediatr Oncol; 2001 Jan; 36(1):231-4. PubMed ID: 11464892 [TBL] [Abstract][Full Text] [Related]
18. Trends in incidence of childhood malignant solid tumors in Japan: Estimation based on hospital-based registration. Ikeda H; Nakamura Y J Pediatr Surg; 2015 Sep; 50(9):1506-12. PubMed ID: 25783293 [TBL] [Abstract][Full Text] [Related]
19. Screening of infants and mortality due to neuroblastoma. Woods WG; Gao RN; Shuster JJ; Robison LL; Bernstein M; Weitzman S; Bunin G; Levy I; Brossard J; Dougherty G; Tuchman M; Lemieux B N Engl J Med; 2002 Apr; 346(14):1041-6. PubMed ID: 11932470 [TBL] [Abstract][Full Text] [Related]